Welcome to our dedicated page for Incannex Healthcare news (Ticker: ixhl), a resource for investors and traders seeking the latest updates and insights on Incannex Healthcare stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Incannex Healthcare's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Incannex Healthcare's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
MELBOURNE, Australia, April 14, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) has appointed Quest Pharmaceutical Services (‘QPS’) to provide regulatory advice and manage clinical trials for its CannQuit™ and ReneCann™ products aimed at addressing addiction and immune-related skin disorders. QPS will handle pre-investigational new drug submissions for both the European Medicines Agency and the US Food and Drug Administration. The CannQuit™ line includes two controlled-release chewing gums combining CBD with nicotine and opioid treatments, while ReneCann™ targets conditions like psoriasis and eczema using a proprietary cannabinoid formulation. These products were acquired from APIRx Pharmaceuticals and are being developed in collaboration with Eurofins Scientific. The global markets for these treatments represent significant economic opportunities for Incannex.
Incannex Healthcare Ltd (NASDAQ: IXHL) is advancing plans to launch multiple psychedelic-assisted psychotherapy clinics in Australia and globally. The first clinic in Melbourne is set to open in 2023 with expectations for rapid expansion. Key board appointments include Dr. Paul Liknaitzky and Professor Suresh Sundram, enhancing clinical expertise. The company views the evolving psychedelic therapy market as a potential multi-billion-dollar opportunity. Ongoing negotiations for premises are at an advanced stage, demonstrating Incannex's commitment to expanding its service delivery beyond research.